Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 14/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | PDE2A | O00408 | 1/20 | 0.34 |
| ▸ | GCG | P01275 | 1/20 | 0.34 |
| ▸ | ALKBH2 | Q6NS38 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | CYP46A1 | Q9Y6A2 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23929998 | 1.00 | EGLN1 (0.47) | EGLN1NPC1ALDH1A1RAB9ACYP1A2 | |
| SCHEMBL23929932 | 0.86 | EGLN1 (0.46) | EGLN1 | |
| SCHEMBL23929930 | 0.86 | EGLN1 (0.46) | EGLN1 | |
| SCHEMBL30257439 | 0.85 | EGLN1 (0.41) | EGLN1NPC1ALDH1A1RAB9AGCG | |
| SCHEMBL23930245 | 0.85 | EGLN1 (0.41) | EGLN1NPC1ALDH1A1RAB9AGCG | |
| SCHEMBL23957697 | 0.85 | EGLN1 (0.41) | EGLN1NPC1ALDH1A1RAB9AGCG | |
| SCHEMBL23930246 | 0.82 | EGLN1 (0.42) | EGLN1NPC1ALDH1A1RAB9AGCG | |
| SCHEMBL23930244 | 0.82 | EGLN1 (0.42) | EGLN1NPC1ALDH1A1RAB9AGCG | |
| SCHEMBL23957691 | 0.76 | EGLN1 (0.43) | EGLN1NPC1ALDH1A1RAB9ACYP1A2 | |
| SCHEMBL28938109 | 0.75 | EGLN1 (0.44) | EGLN1NPC1ALDH1A1RAB9APDE2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159523-A1 | PYRAZOLO[1,5-A]PYRIDINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND COMPOSITION AND USE THEREOF | SHENZHEN ZHONGGE BIOLOGICAL TECHNOLOGY CO., LTD. (CN) | 2023-05-25 | — | — | US | disclosed |
| EP-4141003-A1 | PYRAZOLO[1,5-A]PYRIDINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND COMPOSITION AND USE THEREOF | Shenzhen Zhongge Biological Technology Co., Ltd. (CN) | 2023-03-01 | — | — | EP | disclosed |
| WO-2021213476-A1 | PYRAZOLO[1,5-A]PYRIDINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND COMPOSITION AND USE THEREOF | 深圳晶泰科技有限公司 (CN) | 2021-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159523-A1 | PYRAZOLO[1,5-A]PYRIDINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND COMPOSITION AND USE THEREOF | NCOA4, CCDC47, CCDC6 | EGLN1 3833/4885NPC1 890/4885ALDH1A1 2273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.